. 2023 Dec 15;59(3):315–324. doi: 10.1038/s41409-023-02161-7

Table 3.

Eculizumab treatment and its outcomes.

Pt No	From TMA onset to ECZ initiation(days)	No. of ECZ doses	Prevention of meningococcal infection	PE/PI duration before ECZ initiation (days)	Outcome	Time from TMA onset to last observation/ death (days)	Recurrence of TMA after ECZ discontinuation	Reasons to discontinue ECZ
1^a	6	2	None^b	2	Deceased	29	-	Death
2^a	20	3	Antibiotics	1	Deceased	66	-	Death
3	8	2	None	5	Alive	78	None	Recovered from serious condition^c
4^a	3	5	Antibiotics	0	Deceased	57	-	Death
5	26	64	Antibiotics	14	Alive	1557	None(ECZ ongoing)	-
6^a	126	4	Antibiotics	0	Deceased	182	-	Death
7	8	4	None	4	Alive	182	None	Recovered from serious condition^c
8	8	3	Antibiotics	3	Alive	776	None	Recovered from serious condition^c
9	6	1	Antibiotics	6	Alive	742	None	Insufficient response of platelet count^c
10^a	16	2	None^b	0	Deceased	41	-	Insufficient response of platelet count^c
11^a	62	5	Antibiotics/Vaccination	0	Deceased	125	-	Death
12	19	10	Antibiotics	0	Alive	396	None	Recovered from serious condition^c
13	53	3	Vaccination	12	Alive	172	None	Recovered from serious condition^c
Median (IQR), days	16 (8–26)	3 (2–5)		2 (0–5)	-	172 (66–396)	-

AE adverse event, CFH complement factor H, ECZ eculizumab, LDH lactate dehydrogenase, PLT platelet, Pt patient, TMA thrombotic microangiopathy, WBC white blood cell.

^anon-survivors.

^bAntibiotics were treated for other coexisting infectious disease.

^cTreating physician’s comment in PMS.